

1 **Title:-** Detection of mutations in *gyrB* using denaturing high performance liquid
2 chromatography (DHPLC) among *Salmonella enterica* serovar Typhi and ParatyphiA.

3

4 **Full names of all authors, address of the institute at which the work was performed**

5 Ruchi Gupta^{a,b}, Rajni Gai^{b,*} (Corresponding author), Laishram Chandreshwor Singh^c, Bianca
6 Paglietti^d, Monorama Deb^b, Salvatore Rubino^d, John Wain^{e,**} (Alternative Corresponding author),
7 Seemi Farhat Basir^a

8 a. Department of Biosciences, Jamia Millia Islamia, New Delhi 110025, India.

9 b. Department of Microbiology, Vardhman Mahavir Medical College and Safdarjung Hospital,
10 New Delhi 110029, India.

11 c. National Institute of Pathology, Indian Council of Medical Research, New Delhi 110029,
12 India.

13 d. Department of Biomedical Sciences, Division of Experimental and Clinical Microbiology,
14 University of Sassari. Italy

15 e. Norwich Medical School, University of East Anglia, NRP Innovation Centre, Norwich
16 Research Park, Colney Lane, Norwich, Norfolk NR4 7GJ, United Kingdom.

17

18 **Corresponding author's full address, telephone number and Fax number**

19 **Rajni Gai^{*} (Corresponding author)**

20 Department of Microbiology, Vardhman Mahavir Medical College and Safdarjung Hospital, New
21 Delhi 110029, India. Email ID: rgai5@hotmail.com, Phone no: +91-9810528344, Fax no: 091-
22 11-27123677.

23

24 **John Wain^{e,**} (Alternative Corresponding author)**

25 Norwich Medical School, University of East Anglia, NRP Innovation Centre, Norwich Research
26 Park, Colney Lane, Norwich, Norfolk NR4 7GJ, United Kingdom. Email ID: j.wain@uea.ac.uk,
27 Tel.: +44 (0)1603 59 7567

28

Abstract

29 **Background:-** Fluoroquinolone resistance is mediated by mutations in the quinolone-resistance
30 determining region (QRDR) of the topoisomerase genes. Denaturing high performance liquid
31 chromatography (DHPLC) was evaluated for detection of clinically important mutations in *gyrB*
32 among *Salmonella*.

33 **Method:-** *S. Typhi* and *S. ParatyphiA* characterised for mutation in QRDR of *gyrA*, *parC* and *parE*
34 were studied for mutation in *gyrB* by DHPLC and validated by sequencing.

35 **Result:-** The DHPLC analysis was able to resolve the test mutant from isolates with wild type *gyrB*
36 and distinguished mutants from other mutant by peak profile and shift in retention time. Three
37 sequence variants were detected at codon 464, and a novel mutation Ser→Thr was also detected.
38 *gyrB* mutation was associated with non classical quinolone resistance (NAL^S-CIP^{DS}) in 34 isolates
39 of *S. Typhi* only and was distinct from classical quinolone resistance associated with *gyrA*
40 mutations (NAL^R-CIP^{DS}).

41

42 **Conclusion:** DHPLC is effective for the detection of mutation and can reduce the need
43 for sequencing to detect clinically significant *gyrB* mutations..

44

45 **Accession number:-** (GenBank accession nos. KF993966, GenBank accession no. KF993965 and
46 GenBank accession no. KF993964).

47

48 **Key words:** Decreased Ciprofloxacin Susceptibility, DHPLC, *gyrB* Mutation, *Salmonella Typhi*,
49 *Salmonella Paratyphi A* ,

50 **1. Introduction**

51 *Salmonella enterica* serovar Typhi (*S. Typhi*) and *Salmonella enterica* serovar Paratyphi A
52 (*S. Paratyphi A*) cause the major human infection, enteric fever. The current WHO guidelines state
53 that fluoroquinolones (FQ) are the optimal antimicrobials for treatment of uncomplicated enteric
54 fever.¹ Resistance to quinolones in *S. Typhi* and *S. Paratyphi A* can be caused by amino acid
55 substitutions in the quinolone resistance-determining region (QRDR) of the DNA *gyrase* subunit
56 *gyrA*, a key target of ciprofloxacin (CIP).² These isolates are typically resistant to nalidixic acid
57 (NAL^R, MIC \geq 32 μ g/ml) and show decreased susceptibility to ciprofloxacin (CIP^{DS} MIC
58 >0.064 μ g/ml). Mutations in the QRDR of the other subunit of DNA *gyrase* (*gyrB*) and both subunit
59 of DNA topoisomerases IV (*parC* and *parE*) will also result in increased resistance to quinolones,³
60 however the role of these mutations is not well studied in *S. Typhi* nor *S. Paratyphi A*. Another
61 cause of decreased susceptibility to ciprofloxacin involves mutation in codons 464 (Ser to Phe) and
62 466 (Glu to Asp) of the DNA *gyrase* subunit *gyrB*. These isolates remain sensitive to the
63 recommended screening agent, nalidixic acid,⁴ but infected patients are predicted to show longer
64 times to fever clearance with increased treatment failure following ciprofloxacin therapy.^{2, 5}

65 In diagnostic microbiology laboratories, especially in typhoid endemic regions, the rapid
66 detection of *Salmonella* with decreased susceptibility is important but the most common method,
67 nalidixic acid resistance screening using disc diffusion, is no longer reliable.⁶ To detect mutations in
68 topoisomerase genes, the ultimate method is direct sequencing but this is labour intensive and
69 expensive. Alternative methods to sequencing include: single-strand conformational polymorphism
70 (SSCP), mismatch amplification mutation assay (MAMA-PCR), PCR-restriction fragment length
71 polymorphism (RFLP), high resolution melt analysis⁷ and Light Cycler based PCR-hybridization
72 mutation assay. With the exception of SSCP these methods rely upon mutation-specific oligo-
73 primers (MAMAPCR), mutation-specific oligonucleotide probes (Light Cycler), and mutation-
74 specific enzymes (PCR-RFLP) and so only known mutations can be identified. SSCP relies on
75 differential separation of DNA by gel electrophoresis and does not distinguish all mutations. A

76 method equivalent to direct sequencing in scope but simpler, cheaper and with high sample
77 throughput is needed. Denaturing High Performance Liquid Chromatography (DHPLC) was
78 developed in 1995 and has emerged as a rapid, high throughput screening method to detect
79 mutations and polymorphisms.

80 Mutation detection using DHPLC involves subjecting PCR products, of wild type and test
81 DNA sample in 1:1 mixture, to ion-pair reverse-phase liquid chromatography. Under conditions of
82 partial heat denaturation, heteroduplexes form in PCR samples having internal sequence variation
83 and display reduced column retention time relative to their homoduplex counterparts. Elution
84 profiles for such samples are distinct from those having homozygous sequence, making the
85 identification of samples harbouring polymorphisms or mutations a straight forward procedure.
86 DHPLC is capable of detecting single nucleotide substitutions, small insertions and deletions by
87 online UV or fluorescence monitoring within 10 minutes in unpurified amplicons as large as 1.5 kb.
88 The objective of this study was to evaluate the application of DHPLC, in a developing country
89 setting, as a high throughput tool for detection of clinically important mutations in bacteria using
90 mutations associated with fluoroquinolone resistance in *Salmonella* as a proof of concept.

91

92 **2. Material and methods:-**

93 **2.1 Selection of isolates:-** Two hundred and six isolates of *S. Typhi* ($n=162$) and Paratyphi A
94 ($n=44$), isolated between 2006-2011 were selected to represent diversity in terms of minimum
95 inhibitory concentration (MIC) of nalidixic acid (NAL), ciprofloxacin (CIP), year of isolation and
96 antibiotic resistance profile. MIC for NAL and CIP were determined by E-test (*AB Biodisk, Solna,*
97 *Sweden*). Breakpoints for susceptibility and resistance for NAL and CIP were $\leq 16\mu\text{g/ml}$ and
98 $\geq 32\mu\text{g/ml}$ and ≤ 0.064 and $\geq 1\mu\text{g/ml}$ respectively (CLSI guideline 2012). Decreased ciprofloxacin
99 susceptibility (CIP^{DS}) was defined as MIC > 0.064 $\mu\text{g/ml}$. These isolates had been previously

100 characterised for mutation in QRDR of *gyrA* , *parC* and *parE* genes by PCR amplification and
101 confirmed by direct sequencing.

102 **2.2. PCR**

103 DNA was extracted from isolated bacterial colonies using the Wizard[®] Genomic DNA
104 Purification Kit (Promega) according to the manufacturer's protocol. PCR was used to amplify the
105 QRDR region of *gyrB* of test and control strains using primer FP: 5'-GCG CTG TCC GAA CTG
106 TAC C- 3' and RP: 5'-TGA TCA GCG TCG CCA CTT C-3' with amplicon size 169bp. The
107 primers used in this study were designed in-house using Generunner software (vesion 3.05) and
108 obtained from commercial source (Eurofins, Bengaluru, India). Thermocycler (Gradient
109 Eppendorf) with the following conditions: initial denaturation at 94°C for 5 min, followed by 30
110 cycles of 45 sec at 94°C (denaturation), 45 sec at 50°C (annealing), 45 sec at 72°C (extension), and
111 a final extension of 10 min at 72°C. PCR products were checked by 1.5% agarose gel
112 electrophoresis in 1X TAE buffer. For antibiotic susceptibility tests and PCR *S. Typhi* (Ty2) and *S.*
113 *Paratyphi A* (ATCC9150) strains were used as controls.

114

115 **2.3. DHPLC analysis**

116 The DHPLC analysis was performed using WAVE Nucleic acid fragment analysis system
117 (WAVE System 4500, Transgenomic Inc.). Briefly 5µl of hybridized amplified PCR product of test
118 and wild type strains (Ty2 and ATCC 9150) were mixed in 1:1 ratio. The above mixture of
119 amplimers was hybridized by heating at 95°C for 3min and then cooled gradually by ramping the
120 temperature down to 35°C in 1°C/min steps. The hybridized DNA was loaded on the
121 DNASepCartridge (Transgenomics) with 54% eluent A (0.1 M tri-ethyl-ammonium acetate
122 (TEAA) and 46% eluent B (0.1 M TEAA in 25% (vol/vol) acetonitrile). The predicted average

123 melting temperature over the whole 169bp *gyrB* fragment was 63.3°C. DHPLC analysis was
124 therefore performed at temperatures: 61.3°C, 62.3°C, 63.3°C and 64.3°C at flow rate of 0.9ml/min
125 to optimize formation of duplex DNA in *gyrB* gene. The DNA fragment elution profiles were
126 captured using Transgenomic WAVE MAKER software to determine the correct partial
127 denaturation temperature for mutation scanning based on the sequence of the wild-type DNA from
128 *S. Typhi* (Ty2) and *S. Paratyphi A* (ATCC9150) strains. Eluted DNA fragments were detected by
129 the system's ultraviolet detector. DNA sequence variant detection depends on heteroduplex
130 formation between wild-type and mutant DNA single strands. At elevated temperatures, the less
131 thermostable heteroduplexes start to melt at the mismatched region, and as a result the DNA elutes
132 earlier than corresponding homoduplexes. The optimal temperature to detect mutations in *gyrB*
133 gene was then confirmed empirically by comparing chromatograms (peaks) obtained with retention
134 time for PCR products from wild-type strains. Different peak profile to wild type or same peak
135 profile but with a shift in retention time at a specific temperature were considered to indicate the
136 presence of a mutation. Analyses of wild type DNA of *S. Typhi* (Ty2) and *S. Paratyphi A*
137 (ATCC9150) were performed ten consecutive times to test the reproducibility of retention time.

138

139 **2.4. Sequencing**

140 All isolates of *S. Typhi* and *S. Paratyphi A* had been previously sequenced for *gyrA*, *parC*
141 and *parE* (Table 1). Sequencing was also performed to validate predicted mutations in *gyrB* region
142 detected by DHPLC in 34 *S. Typhi* strains with heteroduplexes and 20 of *S. Typhi* and *S. Paratyphi*
143 *A* strains with homoduplexes.

144 For sequencing, the 50µl of amplified PCR product was run on 2% agarose gel. The desired
145 band of the DNA was excised. The DNA was extracted from the gel by Qiagen gel extraction kit
146 (QIAGEN India Pvt. Ltd, New Delhi, India) and sequencing was done commercially by Macrogen
147 (Korea). For novel mutations sequencing was in duplicate. Sequences obtained were then

148 compared with available sequences on NCBI of *S. Typhi* strain Ty2 (Accession no. NC_004631)
149 and *S. Paratyphi A* strain ATCC9150 (Accession no CP000026) using Finch TV version 1.4.0 and
150 MEGA version 5 software.

151

152 **3. Results**

153 **3.1. Selection of isolates**

154 206 *S. Typhi* and *S. Paratyphi A* isolates were assigned to different groups based on MICs
155 of NAL and CIP, as shown in Table 1. Group 1 included NAL^S-CIP^S isolates, group 2 NAL^R-CIP^{DS}
156 (classical quinolone resistance), Group 3 high level of CIP resistance and Group 4 NAL^S-CIP^{DS}
157 (non classical quinolone resistance); 34/162 *S. Typhi* isolates and 0/44 *S. Paratyphi A* isolates.

158

159 **3.2. Optimal temperature for mutation detection in *gyrB* by DHPLC**

160 A sharp peak of DHPLC chromatograms were obtained at 62.3°C which was identified as
161 the optimal temperature for analysis of mutation in *gyrB* gene for both *S. Typhi* and *Paratyphi A*.
162 Wild type isolates of both serovars gave rise to a single peak at this temperature (homoduplexes).
163 The retention time for DNA for both *S. Typhi* (Ty2) and *S. Paratyphi A* (ATCC9150) isolates at
164 62.3°C was between 4.76 - 4.81 and 3.88 - 3.90 min respectively.

165

166 **3.3. Detection of *gyrB* mutations by DHPLC**

167 We analyzed the *gyrB* QRDR by DHPLC to assess its ability to detect point mutations. A total of
168 206 *isolates of Salmonella* were screened using this method. DHPLC detected 3 DNA sequence
169 variants at Ser464 codon: Ser464-Phe, Ser464-Tyr and Ser 464-Thr which is a novel mutation,

170 Any changes from the single-peak profile characteristic of wild-type *S.Typhi* (Ty2) *S.*
171 *Paratyphi A* (ATCC9150) resulted in formation of heteroduplexes and was indicative of at least one

172 mutation at *gyrB* within the test DNA fragment. Among *S. Paratyphi A* isolates irrespective of their
173 MIC values for ciprofloxacin and nalidixic acid, only a single peak profile characteristic of wild
174 type *gyrB* was observed (Figure 1).

175 Among *S. Typhi* isolates, DHPLC detected four different peak profiles including the wild type as
176 shown in Figure 2. A single-peak profile characteristic of wild-type (Figure 2, peak A) *gyrB* was
177 observed among groups 1, 2 and 3. Heteroduplexes were observed only among group 4 of isolates
178 with non-classical quinolone resistance (NAL^S-CIP^{DS}) indicating the presence of mutation in *gyrB*.
179 All samples containing the same single-base substitutions had identical peak profiles (shown by
180 overlaying them using the WAVEMAKER software). Single mutations at the same point but which
181 incorporated a different substitution were easily seen as different DHPLC peak profiles, for
182 example Ser464-Phe (Figure 2 peak C, $n=31$, (GenBank accession no. KF993966), and Ser464-Tyr
183 (Figure 2 peak D, $n=2$, (GenBank accession no. KF993965). A novel mutation was observed at Ser
184 464-Thr (Figure 2 peak B $n=1$, (GenBank accession no. KF993964). The retention time of these
185 four peak profiles were also distinct (Table 2). Multiple mutations were ruled out by analysis at
186 different temperature.

187

188

189 **3.4. Correlation of NAL and CIP MIC with mutations in DNA *gyrase* and topoisomerase** 190 **genes is shown in Table 1:-**

191 *S. Typhi* and *S. Paratyphi A* group 1 isolates with wild type *gyrA*, *gyrB* and *parC* were
192 susceptible to NAL and CIP (NAL^S-CIP^S). Group 2 isolates of both serovar were uniformly
193 associated with mutation in *gyrA* (Table 1) which conferred classical quinolone resistant phenotype
194 (NAL^R-CIP^{DS}). However among three *S. Typhi* isolates an additional mutation in *parC* gene was
195 also observed. Group 3 isolates with high level of fluoroquinolone resistance were associated with
196 double mutation in *gyrA* and a single mutation in *parC* gene. Mutation in *gyrB* conferred non

197 classical resistance phenotype (NAL^S-CIP^{DS}) among *S. Typhi* only. Although these isolates were
198 nalidixic acid susceptible, they were distinct from group 1 wild type isolates with NAL and CIP
199 MIC being 2-3 and 10 fold higher respectively. The decreased susceptibility to CIP (MIC 0.064-
200 0.5µg/ml) among *gyrB* mutants was twice fold less than decreased susceptibility (MIC CIP 0.064-1)
201 associated with *gyrA* and *parC* mutation among group 1 isolates. Ser 464 Phe was observed most
202 common mutation in *gyrB*. Mutations in *gyrB* did not co-exist with mutation in *gyrA* or *parC* gene
203 and were not observed in *S. Paratyphi A*. No mutations were observed in *parE* gene among both
204 serovars.

205 **4. Discussion:-**

206 DHPLC has been used as a medical research tool since the 1990s to detect polymorphisms
207 in human genes.⁸ More recently DHPLC has also been used for the separation and identification of
208 PCR-amplified fragments from bacterial genes⁹ including: 16S-23S intergenic spacer region (ISR)
209 and *gyrA* gene of *Bacillus anthracis*;¹⁰ and single nucleotide polymorphisms (SNPs) in QRDR of
210 *gyrA* gene for ciprofloxacin resistance in *Salmonella*.¹¹ Methods have also been developed for
211 molecular screening and diagnosis of tumors,¹² and cystic fibrosis.¹³ In this study we have used the
212 DHPLC method for the detect fluoroquinolone resistance in *S. Typhi* and *S. Paratyphi A*. Resistance
213 to quinolones is generally associated with mutation in *gyrA* and *parC*,^{2, 5, 14} and the role of
214 mutation in DNA *gyrase* subunit *gyrB* is less well described. This is probably due to the cost
215 involved in screening all genes from several hundred clinical isolates. In the present study DHPLC
216 was evaluated for its ability to detect SNPs or sequence variation in QRDR of *gyrB* among *S. Typhi*
217 and *Paratyphi A* and results were validated by direct sequencing of amplicons. Major advantages of
218 DHPLC are that knowledge of the exact mutation is within the QRDR of the topoisomerases
219 involved is not necessary; automation is possible; and standard PCR can be used, so this is an ideal
220 method for screening large number of strains. Although sequencing remains a gold standard in

221 SNPs discovery, DHPLC analysis is cheaper and simpler; and novel mutations can be identified.
222 The technique is robust enough to use only one assay for each sample. Mutations are identified by a
223 shift in retention time or a characteristic separation of homo- or heteroduplex peaks. The auto run
224 mode of DHPLC significantly decreases handling time without the loss of assay specificity making
225 screening relatively quick and easy (8 minutes for total run per sample after PCR which includes
226 sample injection, column equilibration, and cleaning). For large numbers of samples automation
227 using 96 well plates can be programmed for repeated injection and analysis at more than one
228 temperature; this makes it a rapid and cost effective. With sufficient evidence to satisfy clinical
229 accreditation this method could be used to rapidly screen for resistance and so reduce the
230 dependences on labour intensive culture based methods. The capital cost is high (approx 110000
231 USD) but running costs are relatively low USD 0.7. The wave maker utility software allows
232 analysis by both overlay of profile (to confirm any subtle changes) and detailed peak data. This
233 allows immediate recognition of identical peaks and those that are novel. Once a library of mutation
234 is generated, sequencing will be necessary only when a novel mutation is observed as distinct
235 peaks.

236 Using DHPLC we correctly identified mutations in *gyrB* in 34 NAL^S *S. Typhi* isolates (MIC
237 $\leq 16\mu\text{g/ml}$). The DHPLC analysis was sensitive and specific and was able to resolve the test mutant
238 from isolates with wild type *gyrB* and distinguished all mutants (with specific changes) from other
239 mutant on the basis of peak profile and shift in retention time. The sequencing data is shown in
240 Figure 3. Sequencing confirmed the DHPLC predicted SNPs. Three sequence variants were
241 detected at codon 464 (Table 2), being Ser464-Phe ($n=31$) the predominant and a novel mutation
242 Ser-464-Thr was also detected. Negative DHPLC results were confirmed by sequencing ($n=20$). It
243 confirms the presence of the wild type (susceptible) sequence rather than the absence of mutation as
244 detected by qPCR methods. All NAL^S isolates with mutations at *gyrB* corresponded to non-classical
245 quinolone resistance phenotype (NAL^S-CIP^{DS}). This is of clear significance in clinical practice as

246 different study groups have already reported that patients infected with isolates showing decreased
247 ciprofloxacin susceptibility normally experience more frequent treatment failures and phenotypic
248 screening with nalidixic acid would not detect *gyrB* mediated resistance. Further *gyrB* mutation was
249 not associated with high level FQ resistance, occurred singly and did not co-exist with other
250 mutations. Previous reports have shown that DHPLC has in addition the advantage of detecting
251 mutations in several regions of the DNA in one test sample.¹¹ Mutations in *gyrB* are rare and
252 multiple mutations were not found.

253

254 **5. Conclusion:-**

255 Our data show that DHPLC can be used to detect mutations in other genes conferring
256 quinolone resistance including genes not normally associated with resistance (*gyrB*) and mutations
257 outside the QRDR region which have not been thoroughly investigated. The high initial cost of the
258 Transgenomic Wave DHPLC may be a factor preventing a wide application of this technique in
259 diagnostic laboratories and further development is needed to perform multiplexed assay for
260 simultaneous detection of mutations in different genes.

261

262 **Authors' disclaimers (if required):- Nil**

263

264 **Authors' contributions:-** JW , RG and BP conceived the study; Ruchi G and SFB designed the
265 study protocol; Ruchi G performed laboratory experiment ; RG, Ruchi G and MD drafted the
266 manuscript, LCS performed DHPLC analysis data; JW and SR edited the final draft of manuscript.
267 RG and SFB are guarantors of the paper. RG, JW and BP prepared the reply for reviewers
268 comments.

269

270 **Acknowledgements (if required):- Nil**

271

272 **Funding:-**

273 This work was supported by Indian Council of Medical Research, Govt. of India. [Grant No.
274 5/8-1(8)2010-11/ECD-II IRIS Cell (ID-2010-04020)] to Dr. Rajni Gaiind.

275

276 **Competing interests:- Nil**

277

278 **Ethical approval**

279 This work was approved by ethics committee (No. 12-10-EC (4/17)).

280

281

282

283

284 **References:-**

- 285 1. The World Health Report. Shaping the future. World Health Organization Geneva 2003.
- 286 2. Turner AK, Nair S, Wain J. The acquisition of full fluoroquinolone resistance in
287 Salmonella Typhi by accumulation of point mutations in the topoisomerase targets. J
288 Antimicrob Chemother 2006; 58: 733-40
- 289 3. Hopkins KL, Davies RH, Threlfall EJ. Mechanisms of quinolone resistance in
290 Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents 2005;
291 25: 358-73.
- 292 4. Song Y, Roumagnac P, Weill FX et al. A multiplex single nucleotide polymorphism
293 typing assay for detecting mutations that result in decreased fluoroquinolone
294 susceptibility in Salmonella enteric serovars Typhi and ParatyphiA. J Anti Chemo 2010;
295 65: 1631-41.

- 296 5. Walia M, Gaiind R, Mehta R et al. Current perspectives of enteric fever: a hospital-based
297 study from India. *Ann Trop Paediatr* 2005; 25: 161-74.
- 298 6. Abbasi S , Imtiaz A, Usman J et al. Evaluation of the current trend of nalidixic acid
299 susceptibility in typhoidal Salmonellae; a marker of therapeutic failure for the
300 fluoroquinolones. *Iran J Microbiol* 2011; 3: 80–83.
- 301 7. Ngoi S T and Thong KL. High Resolution Melting Analysis for Rapid Mutation
302 Screening in Gyrase and Topoisomerase IV Genes in Quinolone-Resistant Salmonella
303 enteric. *Biomed Res Int.* 2014;2014: 718084:8.
- 304 8. Le Maréchal C, Audrézet MP, Quéré I et al. Complete and rapid scanning of the cystic
305 fibrosis transmembrane conductance regulator (CFTR) gene by denaturing high-
306 performance liquid chromatography (D-HPLC): major implications for genetic
307 counselling. *Hum. Genet* 2001; 108: 290-98.
- 308 9. Sagarzazu NI, Martinez M, Algarra C et al. Optimization of denaturing high
309 performance liquid chromatography technique for rapid detection and identification of
310 acetic acid bacteria of interest in vinegar production. *Acetic Acid Bacteria* 2013; 2: e5.
- 311 10. Hurtle W, Bode E, Kaplan RS et al. Use of denaturing high-performance liquid
312 chromatography to identify *Bacillus anthracis* by analysis of the 16S-23S rRNA
313 interspacer region and *gyrA* gene. *J Clin Microbiol* 2003; 41: 4758-66.
- 314 11. Eaves DJ, Liebana E, Woodward MJ et al. Detection of *gyrA* mutations in quinolone-
315 resistant *Salmonella enterica* by denaturing high-performance liquid chromatography. *J*
316 *Clin Microbiol* 2002; 40: 4121-25.
- 317 12. Sivakumaran TA, Kucheria K, Oefner PJ. Denaturing high performance liquid
318 chromatography in the molecular diagnosis of genetic disorders. *Cur Sci* 2003; 84: 291-
319 96.

320 13. D'Apice MR, Gambardella S, Bengala M et al. Molecular analysis using DHPLC of
321 cystic fibrosis: increase of the mutation detection rate among the affected population in
322 Central Italy. BMC Med Genet 2004; 5: 8.

323 14. Gaiand R, Paglietti B, Murgia M et al. Molecular characterization of ciprofloxacin-
324 resistant *Salmonella enterica* serovar Typhi and Paratyphi A causing enteric fever in
325 India. J Antimicrob Chemother 2006; 58:1139-44.

326

327 **Legends**

328

329 **Graph showing overlay of elution pattern of peaks with different retention time for**
330 ***S. Paratyphi A* and *S. Typhi* with mutation in *gyrB* (Figure 1 and Figure 2)**

331

332 **Figure 1.**

333 DHPLC analyses of *S. Paratyphi A* at 62.3°C with mutations in *gyrB* – comparisons with
334 ATCC9150 wild strain by the following peak pattern is showing WT ATCC9150 and test isolates,
335 had no mutation.

336

337 **Figure 2**

338 DHPLC analyses of *S. Typhi* strains at 62.3°C with mutation in *gyrB* region – comparisons with Ty2
339 Wild strain by the following elution of peak patterns: 1) Peak A:-wild type Ty2, had no mutation.
340 2) Peak B:- Ser 464 Thr, 3) Peak C:- Ser 464 Phe and 4) Peak D:- Ser 464 Tyr. Mutations were
341 confirmed by sequencing.

342

343

344 **Figure 3**

345 **Sequence data of showing mutations in *gyrB* at codon 464**

- 346 1. Reference sequence of wild type *gyrB* *S.*TyphiTy2 Accession no. NC_004631.1,
347 2. Ty2 control strain, no mutation as Serine (S) (TCC, Peak A; green colour),
348 3. 780 july /08 sample with mutation Serine to Tyrosine (Y) (TCC→TAC: Peak D; red colour)
349 4. 40 may/10 sample with mutation Serine to Threonine (T) (TCC→ACC, PeakB; blue colour)
350 5. 22 aug/11 sample with mutation Serine to Phenylalanine (F) (TCC→TTC, PeakC; yellow colour)